|
Market Closed -
Xetra
09:05:35 10/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 20.65 EUR | -1.85% |
|
-5.10% | -1.85% |
| 10/09 | GSK gets Japan approval for prefilled Shingrix vaccine | AN |
| 10/09 | GSK Gets Japan Approval for Prefilled Shingrix Syringe | MT |
| Market Cap | 7.11TCr 9.62TCr 8.28TCr 7.81TCr 13TCr 9,20200Cr 13TCr 93TCr 36TCr 4,66700Cr 36TCr 35TCr 14,82400Cr | P/E 2026 * |
13.5x | P/E 2027 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 9.19TCr 12TCr 11TCr 10TCr 17TCr 11,88200Cr 17TCr 1,20100Cr 46TCr 6,02700Cr 47TCr 46TCr 19,14200Cr | EV / Sales 2026 * |
2.71x | EV / Sales 2027 * | 2.51x |
| Free-Float |
92.75% | Yield 2026 * |
3.92% | Yield 2027 * | 4.22% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript : GSK plc
| 1 day | -1.85% | ||
| 1 week | -5.10% | ||
| Current month | -4.97% | ||
| 1 month | -8.47% | ||
| 3 months | -7.27% | ||
| 6 months | -13.31% | ||
| Current year | -1.85% |
| 1 week | 20.65 |  | 21.54 |
| 1 month | 20.65 | | 22.57 |
| Current year | 20.34 | | 26.14 |
| 1 year | 16.73 | | 26.14 |
| 3 years | 14.48 | | 26.14 |
| 5 years | 14.48 | | 27.23 |
| 10 years | 14.48 | | 27.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -5.10% | - | - | 9.79TCr | |
| -0.11% | -3.16% | +48.82% | +91.49% | 1,00200Cr | |
| -0.27% | -4.34% | +51.52% | +65.89% | 64TCr | |
| +1.63% | -2.00% | +20.49% | +71.12% | 44TCr | |
| -0.63% | -3.09% | +29.84% | +34.59% | 34TCr | |
| +0.43% | -14.61% | +11.32% | +27.26% | 26TCr | |
| +0.93% | -3.19% | -1.31% | +8.41% | 24TCr | |
| -2.25% | -13.88% | +37.33% | +47.43% | 21TCr | |
| -0.90% | -5.06% | -18.47% | -57.75% | 20TCr | |
| -0.58% | -4.24% | +25.65% | +90.54% | 18TCr | |
| Average | -0.29% | -5.18% | +22.80% | +42.11% | 39.22TCr | |
| Weighted average by Cap. | +0.02% | -4.39% | +31.98% | +57.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.59TCr 3.95TCr 3.73TCr 6.35TCr 4,39100Cr 6.4TCr 44TCr 17TCr 2,22700Cr 17TCr 17TCr 7,07400Cr | 3.55TCr 4.8TCr 4.13TCr 3.9TCr 6.63TCr 4,59000Cr 6.69TCr 46TCr 18TCr 2,32800Cr 18TCr 18TCr 7,39500Cr |
| Net income | 538.05Cr 727.87Cr 625.97Cr 590.61Cr 1.01TCr 70TCr 1.01TCr 7.03TCr 2.71TCr 35TCr 2.73TCr 2.67TCr 1,12100Cr | 637.41Cr 862.28Cr 741.56Cr 699.68Cr 1.19TCr 82TCr 1.2TCr 8.33TCr 3.21TCr 42TCr 3.24TCr 3.17TCr 1,32800Cr |
| Net Debt | 2.07TCr 2.8TCr 2.41TCr 2.27TCr 3.87TCr 2,68000Cr 3.91TCr 27TCr 10TCr 1,35900Cr 11TCr 10TCr 4,31800Cr | 1.8TCr 2.43TCr 2.09TCr 1.97TCr 3.36TCr 2,32600Cr 3.39TCr 24TCr 9.05TCr 1,18000Cr 9.14TCr 8.94TCr 3,74800Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | €20.65 | -1.85% | 9,820 |
| 09/26/09 | €21.04 | +0.57% | 27,858 |
| 08/26/08 | €20.92 | -2.33% | 21,600 |
| 07/26/07 | €21.42 | -0.37% | 7,237 |
| 04/26/04 | €21.50 | -1.19% | 16,839 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
